Lazard Asset Management LLC purchased a new stake in Agenus Inc. (NASDAQ:AGEN – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 81,126 shares of the biotechnology company’s stock, valued at approximately $157,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Agenus by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 18,402,409 shares of the biotechnology company’s stock worth $45,270,000 after buying an additional 767,856 shares during the last quarter. BlackRock Inc. raised its position in Agenus by 1.7% during the 1st quarter. BlackRock Inc. now owns 17,955,622 shares of the biotechnology company’s stock worth $44,171,000 after buying an additional 305,949 shares during the last quarter. Deep Track Capital LP purchased a new position in Agenus during the 1st quarter worth $34,436,000. Renaissance Technologies LLC raised its position in Agenus by 77.1% during the 1st quarter. Renaissance Technologies LLC now owns 4,922,715 shares of the biotechnology company’s stock worth $12,110,000 after buying an additional 2,143,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Agenus by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,692,344 shares of the biotechnology company’s stock worth $4,164,000 after buying an additional 64,856 shares during the last quarter. Hedge funds and other institutional investors own 51.89% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have commented on AGEN. Sumitomo Mitsui Financial Group began coverage on shares of Agenus in a research report on Wednesday, September 28th. They set an “outperform” rating and a $5.00 price objective for the company. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, November 14th.
Agenus Stock Down 2.3 %
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.